Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose escalation/expansion trial with BYON4228 alone and in combination in metastatic solid tumors
2024-517952-37-00Phase 2Authorised
- Sponsor
- Byondis
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of BYON4228 in cancer and Nonhematologic neoplasms (2 arms), sponsored by Byondis. Planned start Apr 2025; status: authorised.
02
Drugs
BYON4228
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on 2024-517952-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517952-37-00.